DMI-Logo
search-iconsearch-icon
Home
>
News
>
Health care

News

Industry news, company updates, and insights from DataM Intelligence. Stay informed with the latest developments in the industry.

categories

Food and BeverageHealthcareAgricultureChemicals and MaterialsInformation & Communications TechnologyElectronics & SemiconductorEnergy and PowerAutomotive and AviationConsumer-GoodsOthers

Eli Lilly’s Centessa Acquisition Shows Where the Sleep Medicine Market Is Headed

Eli Lilly's acquisition of Centessa Pharmaceuticals marks a strategic expansion into the rapidly evolving sleep medicine market. By adding Centessa's orexin receptor 2 agonist pipeline, including cleminorexton, Lilly strengthens its neuroscience portfolio and positions itself to address narcolepsy, idiopathic hypersomnia, and future wakefulness disorders. This analysis explores the acquisition's strategic rationale, competitive implications, commercial potential, and how orexin biology is transforming the future of sleep medicine.

Jul 3, 2026

AI-Powered Digital Health and Remote Monitoring Redefine Obesity Care Delivery Models in 2026

AI-driven digital health ecosystems and remote monitoring technologies are reshaping obesity care delivery by enabling continuous patient tracking, personalized interventions, and predictive health insights across global healthcare systems.

Jun 29, 2026

AI Platforms Reshape Pharmaceutical Regulatory Workflows, Driving Next-Gen Compliance Automation in 2026

AI-driven platforms are rapidly transforming pharmaceutical regulatory operations by automating compliance documentation, accelerating submissions, and improving global regulatory intelligence across life sciences enterprises.

Jun 18, 2026

FDA Intensifies Oversight of OTC Eye Drop Manufacturing Following Recurring Sterility and Contamination Concerns

The U.S. FDA is intensifying oversight of over-the-counter (OTC) eye drop manufacturers following a series of contamination concerns and sterility-related recalls. The regulatory action highlights growing scrutiny of ophthalmic drug manufacturing practices, quality assurance systems, and compliance with current Good Manufacturing Practices (cGMP). Industry stakeholders are expected to face stricter inspections and increased accountability as regulators work to strengthen patient safety and product quality standards.

Jun 17, 2026